Norfo et al., 2014 - Google Patents
miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesisNorfo et al., 2014
View HTML- Document ID
- 18104167018335335782
- Author
- Norfo R
- Zini R
- Pennucci V
- Bianchi E
- Salati S
- Guglielmelli P
- Bogani C
- Fanelli T
- Mannarelli C
- Rosti V
- Pietra D
- Salmoiraghi S
- Bisognin A
- Ruberti S
- Rontauroli S
- Sacchi G
- Prudente Z
- Barosi G
- Cazzola M
- Rambaldi A
- Bortoluzzi S
- Ferrari S
- Tagliafico E
- Vannucchi A
- Manfredini R
- Publication year
- Publication venue
- Blood, The Journal of the American Society of Hematology
External Links
Snippet
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by megakaryocyte (MK) hyperplasia, bone marrow fibrosis, and abnormal stem cell trafficking. PMF may be associated with somatic mutations in JAK2, MPL, or CALR. Previous studies …
- 208000003476 Primary Myelofibrosis 0 title abstract description 134
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Norfo et al. | miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis | |
Zhang et al. | CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer | |
Hong et al. | Tumor suppressor miRNA-204-5p regulates growth, metastasis, and immune microenvironment remodeling in breast cancer | |
Kubli et al. | AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer | |
Wu et al. | Blocking MIR155HG/miR-155 axis inhibits mesenchymal transition in glioma | |
Netherby et al. | The granulocyte progenitor stage is a key target of IRF8-mediated regulation of myeloid-derived suppressor cell production | |
Starczynowski et al. | Identification of miR-145 and miR-146a as mediators of the 5q–syndrome phenotype | |
Lambiv et al. | The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence | |
Wu et al. | Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer | |
Chou et al. | EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF | |
Emmrich et al. | miR-9 is a tumor suppressor in pediatric AML with t (8; 21) | |
Sun et al. | ABCC4 copy number variation is associated with susceptibility to esophageal squamous cell carcinoma | |
Chen et al. | IKKβ enforces a LIN28B/TCF7L2 positive feedback loop that promotes cancer cell stemness and metastasis | |
Hong et al. | The RNA m6A reader YTHDF1 is required for acute myeloid leukemia progression | |
Zhang et al. | Hsa_circ_0067997 promotes the progression of gastric cancer by inhibition of miR-515-5p and activation of X chromosome-linked inhibitor of apoptosis (XIAP) | |
Shi et al. | miR-663 suppresses oncogenic function of CXCR4 in glioblastoma | |
Zhou et al. | G-MDSCs-derived exosomal miRNA-143-3p promotes proliferation via targeting of ITM2B in lung cancer | |
Wurm et al. | Disruption of the C/EBPα—miR-182 balance impairs granulocytic differentiation | |
Chen et al. | The long coding RNA AFAP1-AS1 promotes tumor cell growth and invasion in pancreatic cancer through upregulating the IGF1R oncogene via sequestration of miR-133a | |
Wong et al. | ADAR1-mediated RNA editing of SCD1 drives drug resistance and self-renewal in gastric cancer | |
Guan et al. | FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer | |
Ye et al. | MicroRNA profiling of serum exosomes in patients with osteosarcoma by high-throughput sequencing | |
Jiang et al. | RETRACTED ARTICLE: Long noncoding RNA RBMS3-AS3 acts as a microRNA-4534 sponge to inhibit the progression of prostate cancer by upregulating VASH1 | |
Zheng et al. | Downregulation of miR-196-5p induced by hypoxia drives tumorigenesis and metastasis in hepatocellular carcinoma | |
Chen et al. | Mecp2-mediated epigenetic silencing of miR-137 contributes to colorectal adenoma-carcinoma sequence and tumor progression via relieving the suppression of c-Met |